Ignite Creation Date:
2025-12-25 @ 1:22 AM
Ignite Modification Date:
2026-02-02 @ 9:02 AM
Study NCT ID:
NCT00258193
Status:
COMPLETED
Last Update Posted:
2006-10-20
First Post:
2005-11-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
Sponsor:
Ironwood Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Irritable Bowel Syndrome | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | C-IBS | View |
| None | IBS-C | View |
| None | Constipation-predominant Irritable Bowel Syndrome | View |
| None | Constipation Predominant Irritable Bowel Syndrome | View |
| None | Irritable Bowel Syndrome | View |
| None | IBS | View |
| None | Transit | View |
| None | Scintigraphy | View |
| None | Gastroenterology | View |
| None | Gastrointestinal | View |
| None | GC | View |
| None | MD-1100 Acetate | View |
| None | MD-1100 | View |
| None | linaclotide | View |
| None | linaclotide acetate | View |